Stockreport

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting scheduled to discuss d [Read more]